Clinical-stage biotechnology company Tempest Therapeutics Inc (Nasdaq: TPST) on Thursday announced an agreement with biotechnology company Roche (SIX: RO, ROG) (OTCQX: RHHBY) to advance the development of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab for the first-line treatment of hepatocellular carcinoma (HCC).
The companies will conduct a pivotal Phase 3 study to evaluate the efficacy and safety of the combination therapy. This follows positive results from a previous Phase 1b/2 study.
Tempest retains all development and commercial rights to amezalpat.
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Novo Holdings launches Booster Therapeutics
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
KeyBioscience extends Eli Lilly collaboration
Tempest to advance amezalpat combination into pivotal trial for HCC